Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Therefore, the Zacks rating upgrade for Lineage Cell basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

We recently compiled a list of the 12 Best Hydrogen and Fuel Cell Stocks to Buy for 2025 ... can outperform the market by imitating the top stock picks of the best hedge funds.